I have not myself assessed the original Suffolk service plan in question - my assessment is of its provenance, and its potential as a prototype for locally co-produced adjustment eg in Norway and Australia. It is not the property of marketeers marketing their highly regulated, importable, medical device (softwares). Naturally the marketeers are extremely keen to validate their national market registrations, which the realistic MEA needs to publish sometime
So given Suffolk's original co-produced plan with its esteemed and highly reputable provenance, and with the high value now unanimously accorded to it, then maybe it is every bit as meticulous and pertinent as it sounds, also making full provision, as recommended, for the required program adjustments. Or at the very least making room for these routine adjustments, hands on, impossible to automate, as follows, for example, as recommended and implemented by our Guideline:
- the case-by-case personal adjustment, as is expected
- use of the patients own words, as is expected
- the right to refuse all or part of a program, and the right to vary drug dosage, etc, as is expected
- adjustable access and advocacy (etc etc), as is expected
- crucially prompt, crucial and ongoing program adjustments to meet all the unpredictable variations of need, as are defined and as expected eg fluctuation, flare-up, and relapse
- local adjustment of commisioned contracts for local service plans, adjustments decided by local commissioners based only on their audited local statistics of local need and affordability, and of course upon local requests from local patients and local professionals as outlined in the Guideline, I think page 2
- medical adjustment by doctors, case by case, based only on their experience and their knowledge of the case